Antineutrophil cytoplasmic autoantibodies and myeloperoxidase autoantibodies in clinical expression of Churg-Strauss syndrome - 30/01/13
Corresponding author: Richard Beasley, DSc, Medical Research Institute of New Zealand, Private Bag 7902, Newtown, Wellington 6242, New Zealand.Abstract |
Background |
The clinical significance of antineutrophil cytoplasmic antibodies (ANCAs) in the phenotypic expression of Churg-Strauss syndrome (CSS) is uncertain.
Objective |
We sought to investigate the relationship between ANCA status and the clinical expression of CSS in a case series derived from the US Food and Drug Administration’s adverse events database.
Methods |
All cases of CSS reported to the US Food and Drug Administration from 1997 to April 2003 were reviewed. Information about basic demographics, suspect medication use, clinical manifestations, histologic findings, ANCA staining patterns, and the presence of antibodies to myeloperoxidase (anti-MPO) or proteinase 3 (anti-PR3) was recorded when available.
Results |
There were 93 case reports of CSS with sufficient documentation, including ANCA status. There were 38 (40.9%) of 93 cases with positive ANCA results, of which 15 cases reported a positive ELISA, all of which were positive for anti-MPO. ANCA negativity was associated with an increased proportion of cardiac involvement (risk difference [RD], 38.2%; 95% CI, 25.3% to 51.0%), gastrointestinal involvement (RD, 25.5%; 95% CI, 13.9% to 37.0%), pulmonary infiltrates (odds ratio, 4.9; 95% CI, 1.5-16.2), and the outcome of a life-threatening event or death (RD, 30.9%; 95% CI, 18.7% to 43.1%) when compared with anti-MPO–positive cases. ANCA negativity was associated with a decreased proportion of peripheral neuropathy (odds ratio, 0.3; 95% CI, 0.07-0.9).
Conclusion |
These findings support the hypothesis that the presence or absence of autoantibodies influences the clinical expression and severity of CSS.
Le texte complet de cet article est disponible en PDF.Key words : Antineutrophil cytoplasmic autoantibodies, Churg-Strauss syndrome, clinical features, US Food and Drug Administration’s Adverse Event Reporting System database, myeloperoxidase
Abbreviations used : AERS, ANCA, Anti-MPO, Anti-PR3, CSS, FDA, IIF, LTRA, MPA, OR, p-ANCA, RD, WG
Plan
| Supported by the Asthma and Respiratory Foundation of New Zealand and the Bowen Trust Board. |
|
| Disclosure of potential conflict of interest: H. Nelson has received consultancy fees from Merck. R. Beasley has received research support from the Asthma and Respiratory Foundation of New Zealand and the Bowen Trust Board. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 131 - N° 2
P. 571 - février 2013 Retour au numéro
Article précédent
- IL-22 suppresses IFN-γ–mediated lung inflammation in asthmatic patients
- Davide Pennino, Pankaj K. Bhavsar, Renate Effner, Simona Avitabile, Pascal Venn, Maria Quaranta, Viviana Marzaioli, Liliana Cifuentes, Stephen R. Durham, Andrea Cavani, Kilian Eyerich, Kian Fan Chung, Carsten B. Schmidt-Weber, Stefanie Eyerich
- Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB
- Mayte Suárez-Fariñas, Julia K. Gittler, Avner Shemer, Irma Cardinale, James G. Krueger, Emma Guttman-Yassky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?